Therapeutics News and Research

RSS

Circadian factors, host gender could help understand microbiome and its effect on inflammatory bowel disease

By now, the old saw, "You are what you eat," has been well-used in describing the microbiome. However axiomatic that phrase may be, a new study has also found that who and when that consumption is done can affect microbiome make-up.

5 Aug 2015

G7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting GPCRs and ion channels

MorphoSys AG and G7 Therapeutics AG announced today that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors and potentially other disease-related transmembrane proteins such as ion channels.

4 Aug 2015

NYSCF scientists design new robotic platform to automate generation of patient-specific stem cells

Scientists at The New York Stem Cell Foundation Research Institute successfully designed a revolutionary, high-throughput, robotic platform that automates and standardizes the process of transforming patient samples into stem cells.

4 Aug 2015

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Researchers at the Johns Hopkins University School of Medicine, Johns Hopkins University Department of Chemical and Biomolecular Engineering, and Federal University of Rio de Janeiro in Brazil have designed a DNA-loaded nanoparticle that can pass through the mucus barrier covering conducting airways of lung tissue — proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases.

4 Aug 2015

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2015 ("Q1 FY16").

3 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain.

3 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.

3 Aug 2015

BUSM researchers find new way to detect and treat basal-like breast cancer

A new way to detect - and perhaps treat - one of the deadliest types of breast cancer has been found. Led by researchers at Boston University School of Medicine (BUSM), the study appears online in Breast Cancer Research.

3 Aug 2015

Researchers quantify growth and composition of breast tumours in living animal

The ability to visualize and characterize the composition of a tumour in detail during its development can provide valuable insights in order to target appropriate therapeutics.

3 Aug 2015

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

New research in mice shows that two commonly used gout medications, which target uric acid and adenosine triphosphate, may offer protection from alcohol-induced liver disease and inflammation.

3 Aug 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015

Researchers gain new insight into the stages of breast cancer growth

The ability to visualize and characterize the composition of a tumour in detail during its development can provide valuable insights in order to target appropriate therapeutics. The polymer chemist Prof. Dr. Prasad Shastri and the pharmacist Jon Christensen, in collaboration with the biomedical researcher Dr. Daniel Vonwil, from the University of Freiburg have visualized and quantified the growth and composition of breast tumours over time in a living animal.

31 Jul 2015

New Penn study questions relevance of fish oil-derived SPMs and their anti-inflammatory effects in humans

The importance of a diet rich in fish oils - now a billion dollar food-supplement industry -- has been debated for over half a century. A few large clinical trials have supported the idea that fish oils confer therapeutic benefits to patients with cardiovascular disease. Researchers think that hearts and blood vessels may benefit in part from their anti-inflammatory properties.

31 Jul 2015

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

UIC, Northwestern University researchers create first artificial ribosome

Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell. The engineered ribosome may enable the production of new drugs and next-generation biomaterials and lead to a better understanding of how ribosomes function.

30 Jul 2015

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the development of new drugs to treat the disease.

30 Jul 2015

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.

29 Jul 2015

New consortium aims to develop precision medicines for globally devastating diseases

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

29 Jul 2015

Therapeutics News and Research

Circadian factors, host gender could help understand microbiome and its effect on inflammatory bowel disease

G7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting GPCRs and ion channels

NYSCF scientists design new robotic platform to automate generation of patient-specific stem cells

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Biosensors’ Q1 FY16 revenue reduces US$67.0M compared to US$80.2M in Q1 FY15

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Omeros receives EC approval to market Omidria in EU and other European countries

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

BUSM researchers find new way to detect and treat basal-like breast cancer

Researchers quantify growth and composition of breast tumours in living animal

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Researchers gain new insight into the stages of breast cancer growth

New Penn study questions relevance of fish oil-derived SPMs and their anti-inflammatory effects in humans

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

UIC, Northwestern University researchers create first artificial ribosome

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

New consortium aims to develop precision medicines for globally devastating diseases

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News